基本信息
浏览量:5
职业迁徙
个人简介
She is a Fellow of the Royal Academy of Engineering (FREng) and a Fellow of Institution of Chemical Engineers (FIChemE).
Specialities: Bioprocess Decisional Tools, Bioprocess Economics, Drug Development Cost Modelling, Capacity planning, Portfolio Management, Risk Analysis, Multi-Criteria Decision-Making, Multi-Objective Simulation & Optimisation, Chemometrics
Suzanne leads research on novel software-based ‘Bioprocess Decisional Tools’ to plan the best route to manufacture of new biotherapeutic candidates. More specifically, she has pioneered the design of novel algorithms at the process-business interface to facilitate cost-effective bioprocess design, capacity planning, and R&D portfolio management through to predictive tools for root cause analysis and manufacturability assessments. These tools have been applied to strategic decisions in the development and manufacture of protein biopharmaceuticals such as monoclonal antibodies (mAbs) and of cell and gene therapies (e.g. MSCs, CAR T-cells, viral vectors). Examples include batch versus continuous manufacture, in-house versus contract manufacturing decisions, factory floor scheduling, centralised versus decentralised manufacture of personalised therapies, facility fit prediction and root cause analysis of deviations in critical quality attributes.
Specialities: Bioprocess Decisional Tools, Bioprocess Economics, Drug Development Cost Modelling, Capacity planning, Portfolio Management, Risk Analysis, Multi-Criteria Decision-Making, Multi-Objective Simulation & Optimisation, Chemometrics
Suzanne leads research on novel software-based ‘Bioprocess Decisional Tools’ to plan the best route to manufacture of new biotherapeutic candidates. More specifically, she has pioneered the design of novel algorithms at the process-business interface to facilitate cost-effective bioprocess design, capacity planning, and R&D portfolio management through to predictive tools for root cause analysis and manufacturability assessments. These tools have been applied to strategic decisions in the development and manufacture of protein biopharmaceuticals such as monoclonal antibodies (mAbs) and of cell and gene therapies (e.g. MSCs, CAR T-cells, viral vectors). Examples include batch versus continuous manufacture, in-house versus contract manufacturing decisions, factory floor scheduling, centralised versus decentralised manufacture of personalised therapies, facility fit prediction and root cause analysis of deviations in critical quality attributes.
研究兴趣
论文共 159 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BIOTECHNOLOGY PROGRESSpp.e3427-e3427, (2024)
Biotechnology and bioengineering (2023)
Biotechnology and bioengineering (2023)
Cell & gene therapy insightsno. 05 (2023): 687-704
引用0浏览0引用
0
0
Stephen Goldrick,Haneen Alosert,Clare Lovelady,Nicholas J Bond, Tarik Senussi,Diane Hatton, John Klein,Matthew Cheeks,Richard Turner,James Savery,Suzanne S Farid
Frontiers in bioengineering and biotechnology (2023): 1160223-1160223
Biotechnology journalno. 11 (2023): e2300194-e2300194
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn